LiVeritas Biosciences

LiVeritas Biosciences is an early stage hybrid life sciences data & analytics company focused on generating transformative mass spectrometry (MS) solutions for the biopharma & pharma (B&P) industries. We collect and analyze data as part of our Mass Spectrometry as a Service (MSaaS) offering, creating automated workflow solutions and software tools enabling development of drug candidates towards more productive clinical outcomes.

✔️ PRODUCT Ready to Go-To-Market NOW: Curated Reagents based upon 100s of workflows developed and implemented in industry settings. More than 50% of which were qualified or validated.
✔️ SEVEN EARLY CLIENTS - Two signed clients, additional five in the next 6 months including a Bay Area Medical School. Pipeline of demand for 2021 when we have a lab: $350K to $800K
✔️Adding another $100K LOI with our fourth biotech client progressing quickly to multi-year and multi-phase Service Agreement and SOW discussions
✔️STRATEGIC RELATIONSHIPS - “Center of Excellence in Biopharma Mass Spec Innovation”, signed and fully executed MOUs with Bruker Scientific LLC and SCIEX
✔️ LAB - Move-in ready lab in South San Francisco for LiVeritas Center of Excellence; Negotiations 95% complete with landlord
✔️ INSTRUMENTS - discounted quotes for state of the art instruments leveraging strategic relationships
✔️ SCIENCE TEAM - Eight Biopharma, System Integration, and Mass Spec Experts, ready to join upon fund-raising as scheduled in 2021

LiVeritas aims to be the industry leader at the intersection of the digital transformation of two big markets: drug development industry ($Tn) and mass spectrometry ($6Bn). “Biopharma 4.0” converges informational, operational, and processing technologies. Our beachhead total addressable market is $22Bn. By targeting pre-clinical testing, we address the high volume segment of drug development, where ALL drug candidates have to be tested. Our potential market includes 2,584 pharma companies with 1-2 drugs in the pipeline, whose budget and demands do not warrant their own in-house mass spec facility, but nevertheless requires quality mass spec analysis for drug identity, purity, and stability.

LiVeritas started out of necessity & opportunity tackling head-on the inefficiency, high cost, & high failure rate of drug development due to poor safety & efficacy. We solve the problems in biopharma mass spec implementation: scarcity of experts, tool fragmentation, inconsistent quality, & slow turn-around-times. Currently, biopharma mass spec experts resort to using multiple fragmented tools requiring them weeks to months to complete projects.

LiVeritas’ 2-pronged solution consists of 1) Mass Spectrometry as a Service (MSaaS) grounded in operational intelligence with quick turnarounds & quality service to de-risk upfront investment and 2) development of end-to-end workflows with software solutions for bio/pharma clients & mass spec hardware vendors. Our pre-clinical testing will be performed by mass spectrometry experts buoyed by AI-software enhanced workflows for high throughput and high quality at fast turnaround times. By driving mass spectrometry testing to pre-clinical testing, our success is not dependent on reaching a clinical phase or on FDA approval, rather all drug candidates go through pre-clinical testing where we provide our services.

We do not have direct competitors in the P/SaaS novel drug development, non-regulated space. Our closest competitors are companies like Seer, PrognomIQ, Nautilus, & Intervenn, all focused on liquid biopsies with a 10-yr horizon for significant revenue growth in the regulated clinical biopharma and CDx spaces.

LiVeritas’ focus is to directly address the unmet needs of bio/pharma clients: an integrated platform of solutions for faster turnaround time from sample submission to actionable insights. The following are items highlights our competitive advantage
*Product Ready to Go-To Market NOW: 100s of workflows implemented in industry settings
*Biopharma 4.0: We move at the speed of biopharma decision makers expediting early intervention in the drug development process
*FASTER: Turnaround time of hours - 7 days
*BETTER: Spot-on Market Fit as we speak the language of clients
*LARGE VOLUME CAPABILITY: up to 35K samples (~$14M)
*Vertical-Agnostic Solutions
*NO FDA REGULATION

Revenue will come from (1) tiered subscription models for the MSaaS and SaaS offerings ($10,000 - $250,00 subscription options) and (2) work contracts for end-to-end workflow solution development and project-based consulting ($5,000 to $250,000 per project). Based on current client demands, we have lined up estimated revenues of $350K to $800K from 7 clients and 2 strategic partners upon lab move-in.

* Launch “Center of Excellence in Biopharma Mass Spec Innovation”
* Unlock Revenue of $600K from 6 clients and 2 partners
* Operational two instruments
* Onboard full-time Dream Team - 4 bio/pharma domain experts and 2 mass spec informatics experts
* Onboard full-time Offshore hybrid chemists/software development leads and create team of 8 software developers,
* Onboard Head of Marketing and Sales
* Onboard new Life Sciences Bioinformatics Technical Advisor who has previous experience as CTO of 4 genomics startups acquired by big pharma companies
* Launch Software Product #1 Demo

As previously mentioned, LiVeritas’ MSaaS offering is positioned to de-risk the upfront investment by leveraging the team’s broad expertise in biopharma mass spec analytics. Some of the risks we foresee are (1) Misinformation of a test result on a drug candidate; however, we plan on avoiding or minimizing this risk through legal agreements; (2) Force majeure (including pandemic) (3) loss of key personnel; and (4) other ordinary and customary business risks.

Expert Dojo Accelerator Program